Anti-IgE Plus Fluticasone Preserves Bone in Asthmatic Mice
Key Takeaways
- In a preclinical ovalbumin-induced chronic murine allergic airway inflammation model, fluticasone propionate plus high-dose anti-IgE was reported as the strongest overall regimen for preserving bone mechanical and mineral integrity.
- Low-dose anti-IgE 100 μg and fluticasone propionate 2000 μg monotherapies were reported as not mitigating allergic airway inflammation-induced bone changes in mice.
- High-dose anti-IgE 200 μg and anti-TNF-α 6.25 mg/kg-bw were described as providing comparable protection across cross-sectional properties, rigidity, energy-to-fracture, elastic modulus, and yield and ultimate moments, while high-dose anti-IgE better preserved calcium, phosphorus, and the stoichiometric Ca/P ratio.
The investigators examined whether persistent type 2-driven inflammation might disrupt skeletal homeostasis during allergic disease. The 56 male BALB/c mice were 8-10 weeks old and weighed 22-24 g, and they were randomly assigned to control, allergic airway inflammation, and five treatment cohorts receiving fluticasone propionate 2000 μg, low-dose anti-IgE 100 μg, high-dose anti-IgE 200 μg, anti-TNF-α 6.25 mg/kg-bw, or the fluticasone propionate/high-dose anti-IgE combination over 8 weeks. The design allowed monotherapy and combination regimens to be compared within the same murine inflammatory setting.
Using three-point bending and ICP-MS, the investigators assessed bone mechanical properties and calcium, phosphorus, and the stoichiometric Ca/P ratio. The named mechanical endpoints were cross-sectional properties, rigidity, energy-to-fracture, elastic modulus, and yield and ultimate moments; within that framework, low-dose anti-IgE and fluticasone propionate monotherapies did not mitigate bone changes, anti-TNF-α and high-dose anti-IgE showed comparable protection across the mechanical outcomes, high-dose anti-IgE better preserved mineral measures, and the combination arm showed the greatest overall preservation. Adverse effects were not described in the abstract, and the authors declared no conflicts of interest.
Clinician Questions
What treatments were compared for bone preservation in the ovalbumin-induced murine allergic airway inflammation model?
In 56 male BALB/c mice with ovalbumin-induced chronic allergic airway inflammation, investigators used an 8-week protocol with random assignment to control, allergic airway inflammation, or treatment cohorts receiving fluticasone propionate 2000 μg, low-dose anti-IgE 100 μg, high-dose anti-IgE 200 μg, anti-TNF-α 6.25 mg/kg-bw, or the fluticasone propionate/high-dose anti-IgE combination.
Which regimen showed the strongest bone mechanical and mineral protection in mice with allergic airway inflammation?
In the murine allergic airway inflammation model, fluticasone propionate plus high-dose anti-IgE was reported as showing the greatest efficacy for preventing mechanical deterioration and preserving mineral integrity. That finding remains specific to the preclinical mouse comparison.
How did high-dose anti-IgE compare with anti-TNF-α for bone outcomes in the murine allergic airway inflammation study?
In mice with allergic airway inflammation, high-dose anti-IgE and anti-TNF-α were reported as providing comparable protection across cross-sectional properties, rigidity, energy-to-fracture, elastic modulus, and yield and ultimate moments, while high-dose anti-IgE was described as more effective for preserving calcium, phosphorus, and the stoichiometric Ca/P ratio.
Recommended Reading
- For more on anti-IgE therapy in asthma: Managing Severe Asthma: 2026 GINA Strategy Report Recommendations
- For more on biologics in asthma care: Respiratory Biologics and Asthma Exacerbation Trends
- For more on biologic treatment in severe asthma: Tezepelumab Reduced Oral Corticosteroid Use in SUNRISE Phase 3 Trial